オリゴヌクレオチド合成の世界市場2019-2023

Technavioが発行した調査報告書(IRTNTR32105)
◆英語タイトル:Oligonucleotide Synthesis Market by End-users and Geography - Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32105
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月
◆ページ数:150
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の本調査レポートでは、オリゴヌクレオチド合成の世界市場について調べ、オリゴヌクレオチド合成の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、オリゴヌクレオチド合成の市場規模をセグメンテーション別(エンドユーザー別(製薬およびバイオテクノロジー企業、研究機関および学術機関、診断検査室、病院)、)と地域別(グローバル)に分けて算出しました。Technavio社はオリゴヌクレオチド合成の世界市場規模が2019-2023期間中に年平均10%成長すると予測しています。
・サマリー
・レポートの範囲
・オリゴヌクレオチド合成の市場状況
・オリゴヌクレオチド合成の市場規模
・オリゴヌクレオチド合成の市場予測
・オリゴヌクレオチド合成の世界環境:ファイブフォース分析
・市場セグメンテーション:エンドユーザー別(製薬およびバイオテクノロジー企業、研究機関および学術機関、診断検査室、病院)
・オリゴヌクレオチド合成の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Oligonucleotide Synthesis Market: About this market

Technavio’s oligonucleotide synthesis market analysis considers sales from pharmaceutical and biotechnology companies, research and academic institutes, diagnostic laboratories, and hospital end-users. Our analysis also considers the sales of oligonucleotide synthesis in Asia, Europe, North America, and ROW. In 2018, the pharmaceutical and biotechnology companies segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increase in research on the development of oligonucleotide therapeutics will play a significant role in the pharmaceutical and biotechnology companies segment to maintain its market position. Also, our global oligonucleotide synthesis market report looks at factors such as the increasing research activities in the pharmaceutical and biotechnology sectors, increasing use of oligonucleotides as therapeutic and diagnostic tools, and emergence of technological innovations in oligonucleotide synthesis. However, regulatory issues associated with oligonucleotide therapeutics, diversity in oligonucleotide molecules, and challenges in effective oligonucleotide delivery may hamper the growth of the oligonucleotide synthesis industry over the forecast period.

Global Oligonucleotide Synthesis Market: Overview

Increasing research activities in the pharmaceutical and biotechnology sectors

The increasing prevalence of chronic and life-threatening diseases has prompted pharmaceutical companies and research firms to focus on R&D activities for the development of effective therapeutics. As a result, advances in life sciences research is leading to an improved understanding of biological systems. The development of oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will lead to the expansion of the global oligonucleotide synthesis market at a CAGR of over 10% during the forecast period.

Increasing focus on R&D of new oligonucleotide therapies

Pharmaceutical and biotechnological companies are focusing on R&D of new oligonucleotide drugs due to the presence of the limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes that are inaccessible by small-molecule drugs and biologic drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Currently, many oligonucleotide therapeutics are in various stages of clinical trials for the treatment of many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers. The presence of these drugs and increase in R&D is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global oligonucleotide synthesis market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global oligonucleotide synthesis market is moderately concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oligonucleotide synthesis manufacturers, that include Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.

Also, the oligonucleotide synthesis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY END-USER

Market segmentation by end-user

Comparison by end-user

Pharmaceutical and biotechnology companies – Market size and forecast

2018-2023

Research and academic institutes – Market size and forecast 2018-2023

Diagnostic laboratories – Market size and forecast 2018-2023

Hospitals – Market size and forecast 2018-2023

Market opportunity by end-user

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing focus on R&D of new oligonucleotide therapeutics

Strategic collaborations and partnerships for oligonucleotide drug discovery

and development

Rise in demand for low-cost and high-throughput oligonucleotide synthesis

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Agilent Technologies Inc.

Danaher Corp.

General Electric Co.

GenScript Biotech Corp.

Kaneka Corp.

Merck KGaA

Nitto Denko Corp.

QIAGEN NV

Sarepta Therapeutics Inc.

Thermo Fisher Scientific Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global healthcare market

Exhibit 03: Segments of global healthcare market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: End-user – Market share 2018-2023 (%)

Exhibit 19: Comparison by end-user

Exhibit 20: Pharmaceutical and biotechnology companies – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Pharmaceutical and biotechnology companies – Year-over-year growth 2019-2023 (%)

Exhibit 22: Research and academic institutes – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Research and academic institutes – Year-over-year growth 2019-2023 (%)

Exhibit 24: Diagnostic laboratories – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Diagnostic laboratories – Year-over-year growth 2019-2023 (%)

Exhibit 26: Hospitals – Market size and forecast 2018-2023 ($ millions)

Exhibit 27: Hospitals – Year-over-year growth 2019-2023 (%)

Exhibit 28: Market opportunity by end-user

Exhibit 29: Customer landscape

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Agilent Technologies Inc. – Vendor overview

Exhibit 49: Agilent Technologies Inc. – Business segments

Exhibit 50: Agilent Technologies Inc. – Organizational developments

Exhibit 51: Agilent Technologies Inc. – Geographic focus

Exhibit 52: Agilent Technologies Inc. – Segment focus

Exhibit 53: Agilent Technologies Inc. – Key offerings

Exhibit 54: Danaher Corp. – Vendor overview

Exhibit 55: Danaher Corp. – Business segments

Exhibit 56: Danaher Corp. – Organizational developments

Exhibit 57: Danaher Corp. – Geographic focus

Exhibit 58: Danaher Corp. – Segment focus

Exhibit 59: Danaher Corp. – Key offerings

Exhibit 60: General Electric Co. – Vendor overview

Exhibit 61: General Electric Co. – Business segments

Exhibit 62: General Electric Co. – Organizational developments

Exhibit 63: General Electric Co. – Geographic focus

Exhibit 64: General Electric Co. – Segment focus

Exhibit 65: General Electric Co. – Key offerings

Exhibit 66: GenScript Biotech Corp. – Vendor overview

Exhibit 67: GenScript Biotech Corp. – Business segments

Exhibit 68: GenScript Biotech Corp. – Organizational developments

Exhibit 69: GenScript Biotech Corp. – Geographic focus

Exhibit 70: GenScript Biotech Corp. – Segment focus

Exhibit 71: GenScript Biotech Corp. – Key offerings

Exhibit 72: Kaneka Corp. – Vendor overview

Exhibit 73: Kaneka Corp. – Business segments

Exhibit 74: Kaneka Corp. – Organizational developments

Exhibit 75: Kaneka Corp. – Geographic focus

Exhibit 76: Kaneka Corp. – Segment focus

Exhibit 77: Kaneka Corp. – Key offerings

Exhibit 78: Merck KGaA – Vendor overview

Exhibit 79: Merck KGaA – Business segments

Exhibit 80: Merck KGaA – Organizational developments

Exhibit 81: Merck KGaA – Geographic focus

Exhibit 82: Merck KGaA – Segment focus

Exhibit 83: Merck KGaA – Key offerings

Exhibit 84: Nitto Denko Corp. – Vendor overview

Exhibit 85: Nitto Denko Corp. – Business segments

Exhibit 86: Nitto Denko Corp. – Organizational developments

Exhibit 87: Nitto Denko Corp. – Geographic focus

Exhibit 88: Nitto Denko Corp. – Segment focus

Exhibit 89: Nitto Denko Corp. – Key offerings

Exhibit 90: QIAGEN NV – Vendor overview

Exhibit 91: QIAGEN NV – Product segments

Exhibit 92: QIAGEN NV – Organizational developments

Exhibit 93: QIAGEN NV – Geographic focus

Exhibit 94: QIAGEN NV – Segment focus

Exhibit 95: QIAGEN NV – Key offerings

Exhibit 96: Sarepta Therapeutics Inc. – Vendor overview

Exhibit 97: Sarepta Therapeutics Inc. – Product segments

Exhibit 98: Sarepta Therapeutics Inc. – Organizational developments

Exhibit 99: Sarepta Therapeutics Inc. – Key offerings

Exhibit 100: Thermo Fisher Scientific Inc. – Vendor overview

Exhibit 101: Thermo Fisher Scientific Inc. – Business segments

Exhibit 102: Thermo Fisher Scientific Inc. – Organizational developments

Exhibit 103: Thermo Fisher Scientific Inc. – Geographic focus

Exhibit 104: Thermo Fisher Scientific Inc. – Segment focus

Exhibit 105: Thermo Fisher Scientific Inc. – Key offerings

Exhibit 106: Validation techniques employed for market sizing

Exhibit 107: Definition of market positioning of vendors



【掲載企業】

Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ オリゴヌクレオチド合成の世界市場2019-2023(Oligonucleotide Synthesis Market by End-users and Geography - Forecast and Analysis 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆